Neuren Pharmaceuticals Limited (ASX:NEU)

Market Cap	1.61B -12.3%
Revenue (ttm)	218.86M +12.1%
Net Income	149.06M +27.1%
EPS	1.15 +28.3%
Shares Out	126.64M
PE Ratio	11.11
Forward PE	62.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	481,622
Average Volume	544,646
Open	13.33
Previous Close	13.57
Day's Range	12.75 - 13.50
52-Week Range	8.61 - 22.99
Beta	1.74
RSI	23.92
Earnings Date	Feb 27, 2026

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NEU

Financial Performance

In 2024, Neuren Pharmaceuticals's revenue was 216.83 million, a decrease of -6.51% compared to the previous year's 231.94 million. Earnings were 142.04 million, a decrease of -9.57%.